Skip to main content

Table 4 Comparison between patients with a residual PSA value at T2 < 1 ng/ml and > 1 ng/ml

From: [68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study

Patients with PSA < 1 ng/ml at T2 (n = 12) Patients with PSA > 1 ng/ml at T2 (n = 9) All patients (n = 21) p value
Irretrievable lesions at T2 [n]: sum; mean 49; 4.1 8; 0.9 57; 2.7 0.007
Irretrievable N and M [n]: sum; mean 45; 3.8 6; 0.67 51 0.007
T2/T1 of PSMA-TV [%]: median (range) 16.7 (0.0–63.5) 52.0 (35.1–207) 38.1 (0.0–207) 0.008
T2/T1 of TL-PSMA [%]: median (range) 6.2 (0.0–94.6) 40.1 (6.0–268) 11.4 (0.0–268) 0.062
T2/T1 of summed miPSMA score [%]: median (range) 29.7 (0.0–80.0) 62.5 (16.7–100) 37.5 (0.00–100) 0.036
Downstaged patients at T2: sum; [%] 8 [66.7%] 3 [33.3%] 11 [52.4%] 0.198
Duration of ADT [days], median, range 190 (98–289) 116 (61–162) 155 (61–289) 0.002
PSA at T1 27.5 (2.5–107.0) 32.9 (18.0–100.4) 29.1 (107.0) 0.925
  1. p values < 0.05 were indicated bold